Teladoc Health just gave shareholders a brutal reminder that cheap can always get cheaper. The stock closed at US$9.18 before the report and is now marked around US$6.58, a slide of more than 28% that wipes out the recent 7 day and 30 day bounce attempts. Yet the headline from the quarter is not a collapse in the core virtual care engine. The story is a pressure point in BetterHelp, where falling cash pay revenue and a thin margin are colliding with a long term bet on insurance based growth.
Is Teladoc Health at a rare value point after this selloff, or is the low P/S ratio just a warning sign in disguise? Compare the current price against our detailed valuation analysis for Teladoc Health.
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs…
